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ABSTRACT
Dyslipidemia is a well-known modifiable risk factor for preventing cardiovascular diseases. The present therapy mainly aiming at pharmacological 
treatment to reduce lipid levels may not be effective in each individual to meet the target levels. Diet and lifestyle modification has an important role 
in treating such chronic illnesses. Nutraceuticals, which are derived from food products, provide one such alternate therapy for the management of 
dyslipidemia. Some of them have proven to be effective for treating dyslipidemia while others require further studies. Much work is still required to 
understand the pharmacokinetics and mechanism of action of these products. Nutraceuticals hold promise in the clinical management of dyslipidemia 
and can be used as primary preventive therapy as more evidence from studies comes in light.
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INTRODUCTION
Globally, cardiovascular disease (CVD) is still the major cause of death, 
which accounts for nearly 17.3 million deaths per year, and this is 
further estimated to grow to nearly 23.6 million by 2030. In 2008, 30% 
of all deaths globally was due to cardiovascular causes with nearly 80% 
of these deaths taking place in low- and middle-income regions [1]. 
Lipid disorders induce vascular damage by inflammation, oxidative 
stress, and immune dysregulation which, in turn, can accelerate the 
process of atherosclerosis and can further increase the risk of CVDs [2]. 
Dyslipidemia is a proven modifiable risk factor for CVDs, and its 
treatment has an important role in preventing these diseases [3-5].
In a meta-analysis done in 2010, it was estimated that by reducing 1.0 
mmol/L (38.7 mg/dL) of low-density lipoprotein-cholesterol (LDL-C), 
there was a corresponding 22% decrease in morbidity and mortality 
due to CVDs [3]. Although pharmacological therapy for dyslipidemia 
such as statins is well-established treatment option, nutritional, and 
lifestyle modification are important in reducing the risk of CVD. It 
is estimated that lifestyle changes and diet can reduce CVD risk by 
82% [6], whereas nutritional practices themselves can reduce the risk 
by 60% [7]. Prolonged pharmacological therapy leads to intolerable 
adverse effects such as myopathy, rhabdomyolysis, raised liver enzymes, 
neuropathy, glucose intolerance, or gastrointestinal disturbances [8].
Thus, safer alternatives are necessary to treat dyslipidemia. Nutraceuticals 
are one such approach which can help reduce lipid levels. Apart from 
their role in dyslipidemia and cardioprotective action, nutraceuticals have 
also been found to have antimicrobial, antidiabetic, anti-inflammatory, 
antineoplastic, hepatoprotective, and neuroprotective action as well [9,10].
These products can act as an alternate to conventional pharmacological 
therapy or adjuvant to them. This review will be focused on nutraceutical 
products and their lipid-lowering effect, some of which are proven to 
control dyslipidemia while others still need more studies to establish 
their role.
NUTRACEUTICALS: DEFINITION AND CLASSIFICATION
The term nutraceutical was coined from nutrition and pharmaceutical 
by Stephen Defelice in 1989. He defined nutraceuticals as “any substance 
that is a food or a part of a food and provides medical or health benefits, 
including the prevention and treatment of disease” [11,12]. Recently, 
the Food Safety and Standards Authority of India in August 2015 has 
defined nutraceutical as “a naturally occurring chemical compound 
having a physiological benefit or provide protection against chronic 
disease, isolated and purified from food or nonfood source and may be 
prepared and marketed in the food format of granules, powder, tablet, 
capsule, liquid, or gel and may be packed in sachet, ampoule, bottle, etc., 
and to be taken as measured unit quantities” [13].
Nutraceuticals are classified into two categories: Traditional and 
nontraditional by Singh and Sinha (2012). The traditional category 
includes all the substances naturally contained in foods, not changed by 
biotechnological techniques, industrial improvements, and/or de novo 
synthesis. The nontraditional nutraceuticals are externally added to the 
foods by bioengineering actions. The two categories are further divided 
into subgroups (Fig. 1).
The traditional category is divided into:
1. Chemical constituents: Herbal and phytochemical products
2. Probiotic microorganisms: Symbiotic bacteria which promote 
digestion and absorption of nutrients
3. Nutraceutical enzymes: Derived from microbial, plant, or animal 
sources.
The nontraditional category is divided into:
1.	 Fortified	nutraceuticals:	These	are	agricultural	and	natural	food	with	
artificially	added	nutrients
2. Recombinant nutraceuticals: Energy providing food produced with 
the help of biotechnology and genetic engineering technology.
NUTRACEUTICALS FOR DYSLIPIDEMIA
Nutraceuticals can effectively reduce the problem of dyslipidemia, 
atherosclerosis, and coronary heart disease (CHD) development as 
already validated in the various studies [14-17]. Nutraceuticals can act 
on several biochemical pathways able to influence lipid disorders in the 
human body. Apart from the lipid-lowering effect, many nutraceuticals 
have antioxidant, antiplatelet, and anti-inflammatory properties which 
further enhances their beneficial role [17-19].
Resveratrol
Resveratrol is a phytoalexin produced by more than 70 different 
plants. Its major concentrations are found in grape, berries, peanuts, 
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and red wine [20]. In 1940, resveratrol was first identified as the 
medicinal component of grapes. It was extracted from the dried roots of 
Polygonum cuspidatum (also known as Ko-jo-kon in Japan) and used in 
the treatment of dyslipidemia [21]. Multiple lipid-lowering mechanisms 
have been proposed for resveratrol such as:
a. It  is similar to statin therapy which acts by inhibiting 
hydroxymethylglutaryl coenzyme A (HMG-CoA) reductase and by 
increasing the ratio of apolipoprotein A1 (apo-A1) with respect to 
apo-B [22].
b. It also promotes reverse cholesterol transport by increasing high-
density lipoprotein (HDL) levels, which is crucial in removing 
cholesterol from the body [23].
c. Adipocytes which store cholesterol promote atherogenesis while 
resveratrol prevents adipogenesis by inducing apoptosis of fat cells 
by silent mating type information regulation 1 homolog and tumor 
necrosis factor (TNF) related apoptosis inducing ligand [24].
d. A study done by Chen et al. hypothesized that the lipid-lowering effect 
of	resveratrol	is	due	to	its	activity	on	cholesterol	7α-hydroxylase.	It	
mediates	 the	conversion	of	 cholesterol	 in	7α-hydroxycholesterol	
and, subsequently, in cholic acid. Bile acids genesis contributes to 
the elimination of cholesterol from plasma [25].
Apart from the lipid-lowering activity, it also has various other beneficial 
effects such as antioxidant, anti-inflammatory, and antiplatelet.
a. Resveratrol does not show any direct scavenging activity of reactive 
oxygen free radical; instead, it upregulates the inbuilt cellular 
antioxidant system which is credited for its protective effects against 
oxidative injury [26].
b.	 The	anti-inflammatory	activity	of	 resveratrol	has	been	shown	by	
inhibiting cyclooxygenase (COX), which mediates conversion of 
arachidonic acid (AA) into thromboxane A2 (TxA2), prostaglandins 
(PGs), and prostacyclins [27,28].
c. Resveratrol also demonstrates its antiplatelet activity by inhibiting 
TxA2 formation by inhibiting COX enzyme. In addition, resveratrol 
inhibits activation of platelets by decreasing the intracellular 
calcium levels ([Ca2+]i) of the platelet. This plays a key role in platelet 
aggregation activity [29].
Although resveratrol is considered as a food supplement for its free 
radical scavenging activity and promoting health, it has still not reached 
the stage for clinical use. Resveratrol has a half-life of 8-14 minutes 
and has been shown to be extensively metabolized in the body. The 
recommended dosage of resveratrol is 250 mg/day [30]. Many clinical 
trials are currently in progress to investigate the beneficial effect and 
safety profile [31].
Soy derivatives
Soybeans contain substances known as soy protein and isoflavones 
which help in decreasing the risk of CVD. Daidzin, genistein, and 
glycitin	are	the	major	isoflavones	and	are	similar	in	structure	to	17-β	
estradiol [32]. These isoflavones attach to estrogen A and B receptors 
and act as a partial estrogen agonist. Among different trails consumption 
of soy proteins reduced lipid levels both in animals and humans, though 
the level of reduction was different in various studies [16]. Soy reduces 
the absorption and micellar content of lipids by fiber, isoflavones, and 
phytoestrogens [33]. Soy proteins increase LDL-receptor (LDL-R) 
expression in human beings [34]. With 30-50 g soy/day, total 
cholesterol (TC), LDL-C, and triglycerides (TGs) decreased by 2-9.3, 
4-12.9, and 10.5%, respectively, with 2.4% increase in HDL-cholesterol 
(HDL-C) [35,36]. A meta-analysis of 29 controlled trials showed that an 
average soy protein consumption of 47 g/day decreased TC levels by 
9%, LDL-C by 12.9%, and TGs by 10.5% with an insignificant effect on 
HDL-C [37]. In 1999, health benefits of soy protein in the reduction of 
CHD due to its cholesterol-lowering effect have been approved by the 
US Food and Drug Administration (FDA) [38].
With recent advances in proteomics, the mechanism of action has 
become clearer. This is helpful in selecting the most appropriate form 
of soy protein for the treatment of dyslipidemia. Soybean contains 
mainly 2 storage proteins 7S and 11S globulins. It was noted that the 
hypocholesterolemic effect of soy protein is mainly due to 7S globulin 
while 11S is the inactive component. The 7S unit is mainly involved 
in upregulation of LDL-R [39,40]. The effectiveness of soy protein as 
proven in various studies reinforces the recommendation to increase 
soy protein in the diet for cardiovascular protection.
Omega-3 fatty acids (FAs)
Long chain omega-3 FA including eicosapentaenoic acid (EPA) and 
docosahexaenoic acid (DHA) are the main components found in fish 
oil. Fish oil can be safely employed in dyslipidemia treatment and has 
been shown to prevent both primary and secondary CVDs in various 
trials. Large-scale epidemiological studies advocate that individuals 
at risk for CHD benefits from the intake of omega-3 FAs, although the 
ideal intake presently is unclear [41,42]. The proposed mechanism for 
this effect seems to be due to reduction in TGs levels, antiarrhythmic 
effects, decreased platelet aggregation, plaque stabilization, 
reduced blood pressure, and a decrease in heart rate [42]. Omega-3 
polyunsaturated FAs (PUFAs) by altering eicosanoid biosynthesis 
affects signaling, changes membrane fluidity which further affects 
enzymatic reactions and binding to a receptor. It directly activates 
factors controlling transcription factor which regulate genes affecting 
hyperlipidemia and inflammation. The mechanism of action for the 
hypotriglyceridemic effect has been identified as upregulation of 
peroxisome	proliferator	activated	receptor	α	(PPAR-α)	in	dyslipidemic	
patients. The administration of these compounds enhance catabolism 
of very LDL (VLDL) by lipoprotein lipase (LPL) and reduce production 
of VLDL by repressing apo CIII and apo B expression. Such an action 
enhances the hypotriglyceridemic effects of these compounds. Apo CII 
(a regulator of LPL activation) expression was downregulated in n-3 
PUFA supplemented patients. Therefore, triacylglycerols clearance 
was improved in treated patients [43]. GISSI prevention study 
demonstrated that omega-3 PUFA supplements lowered mortality, 
sudden cardiac death, and overall cardiovascular deaths by 20%, 45%, 
and 20%, respectively [44]. According to Japan EPA Lipid Intervention 
Study, when statin was combined with 1.8 g of omega-3 FAs results 
obtained showed an additional risk reduction in major coronary 
events and in myocardial infarction (MI) by 19%, and a reduction of 
20% in cerebrovascular events [45]. The diet and reinfarction trial 
showed 29% reduction in death in post-MI men, whereas Kuppio Heart 
Study reported 44% reduction in CHD [45]. Omega-3 FAs decrease 
progression of CHD, prevent restenosis of coronary artery stent, and 
help in plaque stabilization [45]. “Omega-3 index” as proposed by Harris 
and Von schacky, is considered as a risk factor for CHD s and is defined 
as “EPA + DHA as a percentage of total red blood cell FA.” A value of 
8% or above is considered cardioprotective, whereas values below 4% 
are considered to be related with the increase in the risk of CHD [46]. 
Apart from lipid-lowering effect, omega-3 FA has an anti-inflammatory 
and antiplatelet role also. In human diet, the ratio of AA to EPA and 
DHA is important. Fish oil increases EPA in membrane and EPA/AA 
Fig. 1: Nutraceuticals classification
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ratio leading to dampened prostanoid signaling. It mainly acts on COX-
1 mediating the production of PG D, E, and F. Platelets convert EPA to 
TxA3 via COX-1 [47]. EPA increases production of prostacyclin, which 
is platelet antiaggregatory. Increased EPA/AA ratio enhances PGE3 
production from EPA using COX-2 [48].
Berberine
Berberine is a highly concentrated natural isoquinoline alkaloid 
found in numerous medicinal plants (Hydrastis canadensis, Coptis 
chinensis, Berberis aquifolium, Berberis vulgaris, Berberis aristata). It 
is bitter in taste and has bright yellow. It is found in the bark, roots, 
stems, and rhizome of these plants. It has been used traditionally for 
its antimicrobial and antisecretory properties [49]. The substance 
is metabolized by the liver and excreted primarily via the bile after 
glucuronidation. The target organ is mainly the liver, however, 
mechanism of action is complex and not fully clear. Berberine probably 
inhibits the transcription of the mRNA encoding the proprotein 
convertase subtilisin/kexina type 9 (PCSK9). It is the protein that 
facilitates the separation of hepatic LDL-R from the cell surface toward 
the lysosomes where it is usually degraded with a resulting prolongation 
of the receptor’s half-life [50]. This results in an increased expression of 
the LDL-R. Increased LDL-R can then recapture more LDL-C from the 
bloodstream to be sent for excretion via the bile [51]. Berberine may 
also decrease plasma lipids which inhibit cholesterol and TG synthesis 
by activation of adenosine monophosphate-activated protein kinase, 
which further inhibits HMG-CoA reductase [52]. In a study, it was seen 
that berberine decreased TC levels by 29%, TGs levels by 35%, and 
LDL-C by 25%, whereas HDL-C levels remained unchanged [50]. When 
data from 11 randomized controlled trails was analyzed involving 
874 patients with dyslipidemia, Type 2 diabetes mellitus (DM) or with 
both conditions and given berberine ranging from 0.5 g to 1.5 g/day, it 
showed a significant difference between the berberine and the control 
groups. A reduction in TC, LDL-C, and TGs of 23.5 mg/dL, 25.1 mg/dL, 
and 43.8 mg/dL, respectively, was noted while HDL-C was significantly 
increased by 1.93 mg/dL [53]. Some adverse effects of berberine have 
also been noted such as diarrhea, constipation, bloating sensation, 
and bitter taste in the mouth [53]. In another study, the hypoglycemic 
activity of berberine was demonstrated in Type 2 DM. This action is 
proposed to be by improving the resistance to insulin and by increasing 
the expression of insulin receptors [54]. Berberine is one of the most 
interesting nutraceuticals available because of its action on PCSK9 and 
its ability to act on other lipid-lowering pathways as well.
Red yeast rice (RYR)
RYR is a fermented product of rice. Chinese have been using it for 
centuries to make wine from rice, to enhance flavor, as a coloring agent, 
for food and to promote circulation and digestion [55]. In the year 1895, 
yeast Monascus purpureus was obtained from RYR [56]. In 1979, endo 
found a compound produced by this yeast and called it monacolin K, 
which inhibited cholesterol synthesis by a mechanism of action similar 
to statins [57]. There are several kinds of monacolins; they have a 
complex molecular structure which is very similar to that of natural 
statins, in particular to lovastatin. Their metabolism is similar to that of 
the fat-soluble statins, which are quite easily absorbed by the intestine 
as well as metabolized by the isoform 3A4 cytochrome P450 [58]. 
Clinical studies showed that effect on plasma lipid levels was dose 
dependent, with total cholesterol levels reduction of 16-31%, LDL-C 
reduction of 22-32%, TGs reduction of 0-36%, and variable changes 
in HDL-C levels, with an increase up to 20% [59]. The China Coronary 
Secondary Prevention Study investigated RYR for its role in decreasing 
the risk of cardiovascular events. The trial enrolled a total 4870 patients 
who had a history of acute MI and increased cholesterol levels. Patients 
randomized to the test group received Xuezhikang (partially purified 
extract of RYR), and the other group received placebo for a duration of 
4.5 years. Results showed that the group treated with RYR showed a 
reduction in total mortality by 33%, deaths due to cardiovascular events 
by 30%, and the requirement of coronary reperfusion by 33% [59]. 
Another study evaluated the safety and efficacy of RYR in patients with 
statin-associated myalgias. In the RYR group (1800 mg/day, equivalent 
to lovastatin 6 mg), LDL-C reduced by 35 mg/dl [60]. A trial between 
RYR given 2400 mg twice daily and pravastatin given 20 mg twice daily 
showed good tolerance and reasonably good LDL-C decreasing effect 
(30% and 27%, respectively) [61]. FDA, in 2001, said that Cholestin 
(which is a product of RYR) should not be considered as a dietary 
supplement but instead as a drug because it contains lovastatin and 
was associated with statin-related adverse effects [62]. RYR has shown 
good efficacy as lipid-lowering product and can be a good alternative to 
statin intolerant patients.
Curcumin
It is the bioactive compound of turmeric (Curcuma longa). Curcumin 
exhibits anticarcinogenic, anti-inflammatory, antioxidative, anti-
infectious, lipid-lowering, and blood glucose-lowering activity. It 
also blocks activities of TNF, vascular endothelial growth factor, and 
epithelial growth factor [63]. The hypolipidemic effects of curcumin 
are due to: Increase in the LDL-R; increase in enzyme farnesyl 
diphosphate synthase and HMG-CoA reductase; promote sterol 
regulatory element-binding proteins genes; downregulates PPAR [64]. 
It	enhances	the	activity	of	cholesterol-7α-hydroxylase,	which	increases	
the rate of cholesterol breakdown and also increases the hepatic 
superoxide dismutase and glutathione peroxidase leading to decrease 
in oxidation of LDL-C. Curcumin can aggravate bleeding in patients 
who are on anticoagulants. Curcumin also has a protective effect from 
hyperlipidemia induced by alcohol and PUFA. A significant reduction in 
serum levels of lipid peroxides by 33%, decrease in total cholesterol by 
11.6%, and an increase in HDL-C by 29% [65]. Consumption of about 
500 mg/day of good quality curcumin is recommended for the patients.
NUTRACEUTICALS VERSUS LIPID-LOWERING AGENTS
At present, statins are considered as the main first-line treatment for 
dyslipidemia in most hypercholesterolemic patients. It has also been 
proven in various studies that nutraceuticals reduce dyslipidemia 
burden. This action is important when considering patients who are 
intolerant to statins and suffering from severe lipid disorders or whose 
statin treatment is not able to control dyslipidemia and reach the 
desired results. Nutraceuticals could be safely used in these individuals 
to control dyslipidemia and reduce the cardiovascular risk. The reasons 
for recent interest in nutraceuticals as an alternate dyslipidemic 
therapy are mainly due to:
a. Medical treatment cost is increasing around the world
b. Consumers want better preventive therapies for chronic diseases
c. Interest in alternative medical and natural cures
d. Technical advances in the food industry leading development of 
health promoting foods
e. Patients want treatment with less/no side effects compared to 
pharmacological drugs.
In light of the present evidence, it can be said that some nutraceuticals 
can be used as a replacement therapy in the patients who are intolerant 
to the pharmacological therapy while others still need more evidence 
and studies to ascertain their role in lipid-lowering therapy.
FUTURE DIRECTIONS FOR NUTRACEUTICALS
The early 1980s marked the beginning of the revolution of nutraceuticals 
when physicians began to educate their colleagues and consumers 
about these substances due to the various clinical studies done in this 
regard. Japan invented the present concept of nutraceuticals in the 
early 1980s. During the same period, the Japanese health agency to 
control the rising health-care cost, especially due to the rising elderly 
population recognized the need to improve the quality of life and also 
to increase the life expectancy of the elderly population. This lead to 
the development of food products called Foods for Specified Health 
Use mainly to reduce the risk of a disease and promotion of health. 
Presently, consumer interest for health and diet has increased around 
the world because of the recognition of the fact that risk of disease can 
be reduced and one can maintain disease free health with no adverse 
effects through adopting a healthy lifestyle and dietary changes.
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The market for functional food and nutraceuticals has been in existence 
for many years but is less recognized because it is unorganized. The 
future though looks bright but has many challenges such as different 
regulations for different countries, difficulty in claiming the health 
benefits due to no scientific evidence and very less innovation by food 
manufacturing units. Although many countries have legislation for 
regulating such food products, it does not necessarily result in getting 
permission and approval for these products, especially in countries which 
have a strict law for health claim approvals such as the US and Japan [66]. 
Moreover, the nutraceutical industry is still considered as an idea rather 
than reality because it does not clearly differentiate functional foods and 
food supplements which create confusion in minds of consumers. Few 
companies have now begun to understand this problem and are looking 
at better ways to combine both nutritional products along with medical 
treatment to provide a more holistic healthcare.
Globally, nutraceutical and functional food market is expected to grow 
from US $182.60 billion in the year 2015 to US $278.96 billion by the 
year 2021 [67]. Mainly due increase in the elderly population and strong 
over the counter market in various countries. Indian nutraceutical 
market is at a nascent stage but emerging at a fast rate. By the year 2017, 
the growth of nutraceutical market in India is expected to be 70.74% 
when compared to the dietary supplement market. There has been 
a rapid growth in nutraceutical market in India in past few years. The 
main factors which are propelling this market are increasing awareness 
about the availability of different types of nutraceuticals available in 
the market, increase in levels of health consciousness and increase in 
income of people who are now willing to spend on health promoting 
food products. The major presence of the nutraceuticals market of India 
is in the urban parts of the country. The busy lifestyle seen in the urban 
class has encouraged the increase in health consciousness and is driving 
the growth of this industry. The huge population base of India also gives 
a good opportunity for the nutraceutical market to grow in coming years. 
At a compound annual growth rate of 17%, it is projected that the Indian 
nutraceutical market will grow to $4 billion by the year 2018 [68].
CONCLUSION
Functional food and nutraceuticals have the potential to become 
the future of primary prevention in dyslipidemia treatment, and 
secondarily, in CVD prevention because of their established useful 
actions in past studies. The use of substances derived from nutrients 
for lipid-lowering purposes represents a viable alternative to 
commonly used pharmacological therapy. Factors such as changing 
lifestyle, rising awareness about health and fitness, aging population, 
and chronic illnesses are promoting nutraceutical use. Nutraceuticals 
have varied efficacy levels in modifying the lipid levels of the individual. 
Future studies are required to explain the exact pharmacokinetics, 
pharmacodynamics, and mechanism of action of nutraceuticals to 
better adopt these molecules for their therapeutic role in dyslipidemia 
treatment. Proper guidelines for dependability of industrialized 
processes and standardization of the foodstuffs are also needed. 
Escalating the scientific research process which can confirm the efficacy 
and safety of nutraceuticals as lipid-lowering agent can further increase 
the investment in the manufacturing technologies and utilization of 
these products. Although evidence-based medicine does not allow the 
use of such nutraceuticals in modern clinical practice, the use of such 
products has been increasing since the past few years. Once the hurdles 
that limit the role of nutraceuticals have been resolved, its use in various 
disease prevention and treatment will increase in the coming future.
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